Singapore, March 19 -- China's WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organisation (CRDMO), has broken ground on its new 13.5-hectare CRDMO centre in Tuas Biomedical Park, Singapore. The centre will provide integrated biologics research, development and manufacturing services.

WuXi Biologics announced a $1.4 billion (S$2 billion) investment in Singapore in 2022. The CRDMO centre will be the first-of-its-kind in Singapore, offering end-to-end biologics research, development and manufacturing solutions upon completion. It will add 120,000L of manufacturing capacity to WuXi Biologics' global network, and is expected to employ 1,500 staff.

The site will be equipped with WuXi Biologics' proprietary ...